# Xilio Therapeutics Posts $9.98 Million in Q3 2026 Revenue

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/54089
Published: 2026-11-11T14:35:49.000Z
Updated: 2026-11-11T14:35:49.000Z
Section: Business

> Collaboration and license revenue was $10.0 million, compared with $19.1 million a year earlier. Net loss per share was $0.30 on both basic and diluted bases.

Xilio Therapeutics generated $9.98 million in collaboration and license revenue in the third quarter of 2026, while recording a net loss of $0.30 per share on both basic and diluted bases.

The quarter ended Sept. 30. Revenue totaled $9.984 million, rounded to $10.0 million, compared with $19.1 million in the third quarter of 2025.